Oncotelic Therapeutics Reports Q1 2026 Results, Highlights Progress in Oncology and AI Drug Development

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has reported its first-quarter 2026 financial results and provided a corporate update, showcasing continued progress across its diversified biotechnology platform. The company highlighted advancements in its oncology, AI-enabled drug development, and advanced drug delivery initiatives, including developments within its Sapu Nano joint venture and nose-to-brain CNS delivery platform.

According to the press release, Oncotelic maintained the previously established fair value of approximately $388 million for its 45% ownership interest in GMP Biotechnology as of March 31, 2026. The company continues to pursue capital-efficient growth across its platform, which includes a robust pipeline of oncology and immunotherapy products aimed at high-unmet-need cancers and rare pediatric indications.

Oncotelic leverages its proprietary AI-enabled PDAOAI platform to support research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. Additionally, the company benefits from a portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents.

The company also engages in licensing and co-developing select drug candidates through strategic partnerships and joint ventures. Its 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates, further strengthens Oncotelic's position in oncology and rare disease therapeutics.

The full press release is available at https://ibn.fm/DTVsF. For more information about Oncotelic Therapeutics, visit the company's newsroom at https://ibn.fm/OTLC.